AltruBio Overview
- Founded
- 2000
- Status
- Private
- Employees
- 25
- Latest Deal Type
- Series A
- Latest Deal Amount
- $63M
- Investors
- 4
AltruBio General Information
Description
Developer of antibody therapeutics platform designed to assist in the treatment of cancer and immune-related inflammatory diseases. The company's platform focuses on the discovery and development of novel therapeutics for unmet medical needs in the field of antibody-drug conjugates (ADC) therapy as well as creates a linker-payload that can be utilized for different targeted tumor indications, enabling patients with long term drug-free remission of other immune-mediated diseases.
Contact Information
Website
www.altrubio.com
Formerly Known As
AbGenomics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Drug Delivery
Primary Office
- 555 Twin Dolphin Drive
- Suite 310
- Redwood City, CA 94065
- United States
+1 (650) 000-0000
AltruBio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 15-Apr-2021 | $63M | 00000 | Completed | Clinical Trials - Phase 2 | |
| 4. Later Stage VC | 06-Oct-2014 | 0000 | 000.00 | Completed | Clinical Trials - General | |
| 3. Later Stage VC (Series A) | 18-Jul-2013 | 00.00 | 000.00 | Completed | Clinical Trials - General | |
| 2. Later Stage VC | 15-Jun-2012 | $16.9M | $23M | Completed | Clinical Trials - General | |
| 1. Angel (individual) | 16-Jul-2008 | $6.15M | $6.15M | Completed | Clinical Trials - General |
AltruBio Patents
AltruBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017206074-A1 | Tetravalent anti-psgl-1 antibodies and uses thereof | Pending | 08-Jan-2016 | 00000000000 | |
| CA-3010601-A1 | Tetravalent anti-psgl-1 antibodies and uses thereof | Pending | 08-Jan-2016 | 00000000000 | |
| CA-2952876-A1 | Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof | Pending | 20-Jun-2014 | 00000000000 | |
| AU-2015276821-A1 | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof | Abandoned | 20-Jun-2014 | 00000000000 | |
| EP-3157960-A4 | Anti-folate receptor aplha (fra) antibody-drug conjugates and methods of using thereof | Withdrawn | 20-Jun-2014 | A61K47/6803 | 0 |
AltruBio Executive Team (14)
AltruBio Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Corsee Sanders Ph.D | Self | Board Member | 000 0000 |
| Gur Roshwalb MD | aMoon Fund | Board Member | 000 0000 |
| John Doyle | Self | Board Member | 000 0000 |
| Patrick Yang Ph.D | Self | Chairman | 000 0000 |
| Sean Bohen MD | Self | Board Member | 000 0000 |
AltruBio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialAltruBio Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| aMoon Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BVF Partners | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| CAM Capital | Asset Manager | Minority | 000 0000 | 000000 0 | |
| EVX Ventures | Venture Capital | Minority | 000 0000 | 000000 0 |